Effects of Enzyme Replacement Therapy and Antidrug Antibodies in Patients with Fabry Disease

被引：76

作者：

Lenders, Malte ^{[1
]}

Brand, Eva ^{[1
]}

机构：

[1] Univ Hosp Muenster, Dept Nephrol Hypertens & Rheumatol, Internal Med D, Albert Schweitzer Campus 1, D-48149 Munster, Germany

来源：

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2018年 / 29卷 / 09期

关键词：

antibodies; Fabry disease; immunosuppression; infusion associated reactions; treatment; AGALSIDASE-BETA THERAPY; HUMAN ALPHA-GALACTOSIDASE; PHARMACOLOGICAL CHAPERONE MIGALASTAT; SUBSTRATE REDUCTION THERAPY; IMMUNE MODULATION THERAPY; POMPE-DISEASE; CLINICAL-MANIFESTATIONS; MEMBRANOUS NEPHROPATHY; DOSE REDUCTION; RENAL-FUNCTION;

D O I：

10.1681/ASN.2018030329

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：2265 / 2278

页数：14

共 125 条

[1]

[Anonymous], 2018, AMICUS THERAPEUTICS

[2] Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study [J].

Arends, Maarten ;

Biegstraaten, Marieke ;

Wanner, Christoph ;

Sirrs, Sandra ;

Mehta, Atul ;

Elliott, Perry M. ;

Oder, Daniel ;

Watkinson, Oliver T. ;

Bichet, Daniel G. ;

Khan, Aneal ;

Iwanochko, Mark ;

Vaz, Frederic M. ;

van Kuilenburg, Andre B. P. ;

West, Michael L. ;

Hughes, Derralynn A. ;

Hollak, Carla E. M. .

JOURNAL OF MEDICAL GENETICS, 2018, 55 (05) :351-358

[3] Favourable effect of early versus late start of enzyme replacement therapy on plasma globotriaosylsphingosine levels in men with classical Fabry disease [J].

Arends, Maarten ;

Wijburg, Frits A. ;

Wanner, Christoph ;

Vaz, Frederic M. ;

van Kuilenburg, Andre B. P. ;

Hughes, Derralynn A. ;

Biegstraaten, Marieke ;

Mehta, Atul ;

Hollak, Carla E. M. ;

Langeveld, Mirjam .

MOLECULAR GENETICS AND METABOLISM, 2017, 121 (02) :157-161

[4] Efficacy of Enzyme and Substrate Reduction Therapy with a Novel Antagonist of Glucosylceramide Synthase for Fabry Disease [J].

Ashe, Karen M. ;

Budman, Eva ;

Bangari, Dinesh S. ;

Siegel, Craig S. ;

Nietupski, Jennifer B. ;

Wang, Bing ;

Desnick, Robert J. ;

Scheule, Ronald K. ;

Leonard, John P. ;

Cheng, Seng H. ;

Marshall, John .

MOLECULAR MEDICINE, 2015, 21 :389-399

[5] Biomarkers associated with clinical manifestations in Fabry disease patients with a late-onset cardiac variant mutation [J].

Auray-Blais, Christiane ;

Lavoie, Pamela ;

Boutin, Michel ;

Ntwari, Aime ;

Hsu, Ting-Rong ;

Huang, Chun-Kai ;

Niu, Dau-Ming .

CLINICA CHIMICA ACTA, 2017, 466 :185-193

[6] Urinary biomarker investigation in children with Fabry disease using tandem mass spectrometry [J].

Auray-Blais, Christiane ;

Blais, Catherine-Marie ;

Ramaswami, Uma ;

Boutin, Michel ;

Germain, Dominique P. ;

Dyack, Sarah ;

Bodamer, Olaf ;

Pintos-Morell, Guillem ;

Clarke, Joe T. R. ;

Bichet, Daniel G. ;

Warnock, David G. ;

Echevarria, Lucia ;

West, Michael L. ;

Lavoie, Pamela .

CLINICA CHIMICA ACTA, 2015, 438 :195-204

[7] How well does urinary lyso-Gb3 function as a biomarker in Fabry disease? [J].

Auray-Blais, Christiane ;

Ntwari, Aime ;

Clarke, Joe T. R. ;

Warnock, David G. ;

Oliveira, Joao Paulo ;

Young, Sarah P. ;

Millington, David S. ;

Bichet, Daniel G. ;

Sirrs, Sandra ;

West, Michael L. ;

Casey, Robin ;

Hwu, Wuh-Liang ;

Keutzer, Joan M. ;

Zhang, X. Kate ;

Gagnon, Rene .

CLINICA CHIMICA ACTA, 2010, 411 (23-24) :1906-1914

[8]

Aydin Ö, 2013, J INVEST ALLERG CLIN, V23, P367

[9] Enzyme replacement therapy in heterozygous females with Fabry disease: Results of a phase IIIB study [J].

Baehner, F ;

Kampmann, C ;

Whybra, C ;

Miebach, E ;

Wiethoff, CM ;

Beck, M .

JOURNAL OF INHERITED METABOLIC DISEASE, 2003, 26 (07) :617-627

[10] Gastrointestinal manifestations of Fabry disease: Clinical response to enzyme replacement therapy [J].

Banikazemi, M ;

Ullman, T ;

Desnick, RJ .

MOLECULAR GENETICS AND METABOLISM, 2005, 85 (04) :255-259

← 1 2 3 4 5 6 7 8 9 10 →